Addressing Adverse Effects, Adherence, & Drug Discontinuation to Manage Treatment Burden in IPF

• Understanding the real-world challenges associated with current antifibrotic therapies, including gastrointestinal side effects, tolerability issues, and the high annual discontinuation rates seen in clinical practice
• Exploring strategies to improve treatment adherence and quality of life through supportive care, dose optimization, and multidisciplinary management approaches
• Discussing how future therapies and trial designs may reduce treatment burden while maintaining clinical benefit for patients living with IPF

Speakers:

Franck Rahaghi

Executive Director - Cardiopulmonary & Global Medical Affairs

United Therapeutics Corp.